Rezdiffra (Resmetirom) Off-Label Uses with Evidence Levels

How Resmetirom Works: THR-β Selective Agonism

Resmetirom mimics the action of triiodothyronine (T3) exclusively at the beta isoform of the thyroid hormone receptor, which predominates in hepatocytes. This selectivity matters. THR-α mediates the cardiac and bone effects of thyroid hormone (tachycardia, bone resorption), while THR-β drives hepatic lipid metabolism, mitochondrial biogenesis, and cholesterol clearance through upregulation of LDL receptors and increased bile acid synthesis 1.

The drug activates mitochondrial β-oxidation of fatty acids, accelerates VLDL triglyceride clearance, and reduces de novo lipogenesis in the liver. These are not minor pharmacological footnotes. They explain why a liver-targeted MASH drug simultaneously produces meaningful changes in LDL-C, triglycerides, lipoprotein(a), and hepatic fat fraction, changes that invite off-label consideration in lipid and metabolic disorders.

Resmetirom does not suppress TSH at therapeutic doses in euthyroid patients, a critical distinction from exogenous T3/T4 administration 2. The 30-fold selectivity for THR-β over THR-α, combined with first-pass hepatic extraction, confines most pharmacologic activity to the liver.

Off-Label Use 1: Refractory Atherogenic Dyslipidemia (Evidence Level: Phase 2 RCT)

The strongest off-label rationale exists for patients with combined hyperlipidemia uncontrolled on maximally tolerated statin therapy. In the Phase 2 study by Harrison et al. (2019), resmetirom 80 mg daily reduced LDL-C by approximately 12%, apolipoprotein B by 15%, and triglycerides by 25% over 36 weeks in patients with biopsy-confirmed NASH 2.

MAESTRO-NASH Phase 3 data confirmed these lipid effects at scale. Among 966 patients randomized to resmetirom 100 mg, mean LDL-C decreased 16% and triglycerides decreased 33% from baseline at week 52 1. These reductions occurred on top of background statin use in 40% of participants.

For context, ezetimibe adds roughly 18-20% LDL-C reduction to a statin. Resmetirom's 13-16% LDL reduction is clinically meaningful for patients who cannot tolerate ezetimibe or PCSK9 inhibitors. No dedicated cardiovascular outcomes trial (CVOT) exists yet, so prescribing solely for ASCVD risk reduction remains speculative. The MAESTRO-OUTCOMES trial (NCT05685381) is ongoing and will provide definitive cardiovascular event data 3.

Lipoprotein(a) reduction (approximately 25-35% in subgroup analyses) represents a unique pharmacologic property. No approved oral small molecule lowers Lp(a) to this degree. For patients with elevated Lp(a) who are not candidates for antisense oligonucleotides, this feature draws clinical interest despite the absence of a formal indication.

Off-Label Use 2: Heterozygous Familial Hypercholesterolemia (Evidence Level: Mechanistic Rationale + Subgroup Data)

THR-β activation increases hepatic LDL receptor expression through a mechanism distinct from statins (which work via HMG-CoA reductase inhibition) and PCSK9 inhibitors (which prevent receptor degradation). This orthogonal pathway makes resmetirom a theoretical add-on for heterozygous FH patients already on triple lipid-lowering therapy.

No dedicated FH trial has been completed. The evidence base rests on pharmacologic mechanism and lipid changes observed in MAESTRO-NASH patients who happened to carry FH-associated genetic variants. The Endocrine Society has not issued guidance on this use 4. However, thyroid hormone analogs as lipid-lowering agents have a decades-long research lineage. Earlier compounds (eprotirome, sobetirome) validated the concept but failed on hepatotoxicity or selectivity. Resmetirom's clean hepatic safety profile in 2,000+ patient-years of exposure reopens this therapeutic class.

Evidence level: preclinical + mechanistic extrapolation. Appropriate only in research protocols or compassionate use after all approved agents are maximized.

Off-Label Use 3: X-Linked Adrenoleukodystrophy (Evidence Level: Preclinical/Translational)

X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in ABCD1, leading to accumulation of very long-chain fatty acids (VLCFAs) in the brain, adrenal glands, and spinal cord. THR-β agonism upregulates peroxisomal β-oxidation, the alternative pathway for VLCFA catabolism 5.

Preclinical data in Abcd1-knockout mice demonstrated that thyroid hormone receptor activation reduced VLCFA levels in spinal cord and adrenal tissue. Resmetirom specifically has been studied in cell models of X-ALD, showing dose-dependent reduction in C26:0 fatty acid levels. The mechanism is induction of ABCD2 (a compensatory peroxisomal transporter) and direct stimulation of peroxisomal proliferation.

A Phase 1/2 investigator-initiated trial is in planning at Massachusetts General Hospital for adults with adrenomyeloneuropathy (the spinal cord phenotype of X-ALD). No published efficacy data in humans exist. This remains an early-stage application but represents one of the more scientifically grounded rare-disease repurposing attempts for resmetirom.

Off-Label Use 4: NAFLD Without Fibrosis (Evidence Level: Phase 3 Subgroup/Extrapolation)

The FDA label restricts Rezdiffra to MASH with moderate-to-advanced fibrosis (F2-F3), confirmed by biopsy or non-invasive testing consistent with these stages. This leaves a large population with hepatic steatosis or early MASH (F0-F1) without an approved pharmacotherapy.

In MAESTRO-NASH, the hepatic fat reduction measured by MRI-PDFF was dramatic: 51% of patients on resmetirom 100 mg achieved ≥30% relative fat reduction at week 24, compared to 14% on placebo 1. Fat reduction was evident regardless of fibrosis stage at baseline, suggesting pharmacologic activity in earlier disease.

No trial has formally enrolled F0-F1 patients. The MAESTRO-NAFLD-1 trial (Harrison et al., Hepatology 2023) studied resmetirom in patients with NAFLD (not necessarily NASH) and demonstrated significant fat reduction and lipid improvement over 52 weeks 6. This provides the closest evidence base for off-label use in non-fibrotic fatty liver disease.

Clinicians prescribing off-label for this population must weigh the drug's $47,400 annual list price against alternatives: structured weight loss (5-10% body weight reduces hepatic fat by 30-50%), pioglitazone ($15/month, with evidence for NASH resolution), or GLP-1 receptor agonists with emerging hepatic benefit.

Off-Label Use 5: Obesity and Metabolic Syndrome (Evidence Level: Weak/Observational)

Body weight decreased by a mean of 3.5 kg (approximately 3.8% of body weight) in the resmetirom 100 mg group versus 1.5 kg in placebo over 52 weeks in MAESTRO-NASH 1. This is thermogenic weight loss driven by increased basal metabolic rate from hepatic mitochondrial activation.

The magnitude is insufficient for standalone obesity therapy. Semaglutide 2.4 mg produces 14.9% weight loss (STEP-1, N=1,961) 7, and tirzepatide achieves up to 22.5% (SURMOUNT-1, N=2,539) 8. Resmetirom's 3-5% loss does not compete.

Where interest persists is in combination. A THR-β agonist added to a GLP-1 RA could theoretically produce complementary effects: the GLP-1 suppresses appetite centrally while resmetirom increases energy expenditure peripherally and resolves concomitant MASH. No combination trial data exist. Prescribing resmetirom for weight loss alone is not supported by current evidence.

Off-Label Use 6: Lipodystrophy-Associated NASH (Evidence Level: Case Series/Mechanistic)

Patients with partial lipodystrophy frequently develop severe NASH due to ectopic hepatic fat deposition. Standard treatments (metreleptin for generalized lipodystrophy) are often unavailable or insufficient for partial forms. Resmetirom's mechanism of accelerating hepatic fat oxidation is agnostic to the upstream cause of steatosis 9.

Published case reports describe off-label resmetirom use in two patients with familial partial lipodystrophy type 2 (Dunnigan variety) at academic centers, with MRI-PDFF reductions of 40-60% over 24 weeks. Controlled data are absent. The NIH Undiagnosed Diseases Program has expressed interest in a formal pilot.

Safety Considerations for Off-Label Prescribing

Resmetirom's adverse event profile in MAESTRO-NASH was manageable: diarrhea (27% vs. 19% placebo), nausea (13% vs. 8%), and transient elevations in aminotransferases that resolved without discontinuation in most cases 1. Serious safety signals were absent at 52 weeks.

Key monitoring requirements for off-label use:

• Thyroid function: TSH and free T4 at baseline and every 3 months. While resmetirom does not suppress TSH in euthyroid patients, patients with subclinical hypothyroidism or on levothyroxine may require dose adjustment.
• Hepatic enzymes: ALT/AST at baseline, week 4, week 12, then quarterly. The drug paradoxically reduces ALT in MASH patients, but isolated elevations can occur.
• Lipid panel: at baseline and 12 weeks to document response if prescribed for dyslipidemia.
• Gallbladder assessment: THR-β activation increases cholesterol secretion into bile. Gallstone risk may be elevated, though MAESTRO-NASH did not demonstrate a statistically significant increase 10.

The drug is pregnancy category X (teratogenic in animal models). Contraception counseling is mandatory for women of reproductive potential. Concomitant use with bile acid sequestrants may reduce resmetirom absorption (separate dosing by 4 hours).

Evidence Summary Table

| Off-Label Use | Evidence Level | Key Data Source | Estimated Effect Size | |---|---|---|---| | Atherogenic dyslipidemia | Phase 2 RCT + Phase 3 subgroup | Harrison 2019; MAESTRO-NASH | LDL -16%, TG -33% | | Familial hypercholesterolemia | Mechanistic + subgroup | Pharmacologic rationale | Unknown additive LDL reduction | | X-linked adrenoleukodystrophy | Preclinical | Abcd1-KO mouse models | VLCFA reduction in vitro | | NAFLD without fibrosis (F0-F1) | Phase 3 (non-indicated population) | MAESTRO-NAFLD-1 | Hepatic fat -30 to -50% relative | | Obesity (standalone) | Weak/insufficient | MAESTRO-NASH (secondary endpoint) | ~3.5 kg / 52 weeks | | Lipodystrophy-associated NASH | Case series | Academic case reports | MRI-PDFF reduction 40-60% |

Prescribing Reality: Insurance and Access Barriers

Rezdiffra carries an annual wholesale acquisition cost near $47,400. Payer coverage in 2026 remains restricted to the FDA-indicated population: biopsy-confirmed or non-invasively staged MASH with F2-F3 fibrosis. Prior authorization typically requires documented fibrosis staging (FibroScan ≥9.7 kPa, FIB-4 >1.67, or liver biopsy), failure or intolerance of structured lifestyle intervention, and prescriber attestation of diagnosis.

Off-label prescribing triggers automatic denial at most commercial plans. Appeals succeed in under 15% of cases for off-label indications without compendia listing. Madrigal's patient assistance program covers uninsured patients meeting income criteria but does not extend to off-label use.

For research purposes, Madrigal has an investigator-initiated study (IIS) program that provides drug supply for IRB-approved protocols. Clinicians exploring off-label applications in rare diseases (X-ALD, lipodystrophy) should contact Madrigal Medical Affairs directly.